Outcomes of a Digital Mindfulness Meditation App-Based Intervention in Adolescents With Moderate to Severe Atopic Dermatitis (MIND-AD)
Weill Medical College of Cornell University
Summary
Atopic dermatitis is well reported to have a significant impact on well-being in adolescents with atopic dermatitis, without clear recommendations for intervention. The investigators aim to identify an accessible, effective digital health intervention for these patients. The investigators hypothesize that regular use of a digital mindfulness meditation app will improve disease control and quality of life in adolescents with moderate to severe atopic dermatitis based on validated survey measures.
Description
Atopic dermatitis (AD) is a significant chronic, relapsing, remitting, disease affecting children and adolescents, in terms of prevalence and impact on patient quality of life. Ten percent of individuals in the United States have AD, with prevalence peaking during childhood and adolescence. Over the past 25 years, prevalence of AD in has increased from 8% to 12%. Atopic dermatitis is known to significantly impact patient quality of life. Pruritis is known to be among the most burdensome symptoms. Many patients report severe pruritis significantly affecting sleep. Children and adolescents with…
Eligibility
- Age range
- 12–17 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria * Adolescents age 12-17 years. * Atopic dermatitis refractory to standard topical treatment including topical steroids or topical calcineurin inhibitors. * Moderate to severe atopic dermatitis via PO-SCORAD score on enrollment. Exclusion Criteria * Started on a biologic agent (i.e. dupxient) within the past 3 months. * Mild atopic dermatitis via PO-SCORAD score on enrollment.
Interventions
- BehavioralDigital App Mindfulness Meditation
Regular use of a digital mindfulness meditation app 3-4 times per week for 10-15 minutes each session.
- BehavioralMindfulness Meditation Sheet
Participants will read an informational handout on mindfulness meditation at the start of the study.
Locations (2)
- Weill Cornell MedicineNew York, New York
- Columbia University Irving Medical CenterNew York, New York